Send us Feedback

Omeros Corp (OMER)
Analysis
SUMMARY
BULLS
BEARS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Omeros (OMER) Approved to Commence OMS721 Phase 1
StreetInsider.com  Jun 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Omeros+%28OMER%29+Approved+to+Commence+OMS721+Phase+1/8413101.html for the full story.
Omeros (OMER) Reports Encouraging Update from OMS824 Phase 1
StreetInsider.com  May 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Omeros+%28OMER%29+Reports+Encouraging+Update+from+OMS824+Phase+1/8381304.html for the full story.
Omeros (OMER) Files CTA in Europe for OMS721 Trials
StreetInsider.com  May 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Omeros+%28OMER%29+Files+CTA+in+Europe+for+OMS721+Trials/8370808.html for the full story.
Omeros Announces INDA for OMS824 in Huntington's Disease Cleared by FDA
Benzinga  May 23  Comment 
Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits...
Traders in Omeros Attributing Upside in Shares to Bullish Note from MLV & Co., Says Trend Higher 'Will Continue'
Benzinga  May 14  Comment 
McNicoll Lewis Vlak & Co.'s George Zavoico issued a research note Tuesday highlighting some positive feedback from physicians on Omeros Corp.'s (NASDAQ: OMER) OMS302 at the Association for Research in Vision and Ophthalmology. The analyst...
Omeros Announces 3.9M Share Direct Offering of Common Stock at $4.14/Share
Benzinga  May 9  Comment 
Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The...
Omeros Corp. (OMER) Reports In-Line Q1 EPS
StreetInsider.com  May 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Omeros+Corp.+%28OMER%29+Reports+In-Line+Q1+EPS/8324266.html for the full story.
WBB Pounds the Table on Omeros Following Orphan Drug Status, Maintains Strong Buy Rating, $20 Target
Benzinga  Apr 18  Comment 
WBB Securities maintains Omeros Corporation (NASDAQ: OMER) with a Strong Buy and maintains $20.00 PT. The firm's Stephen Brozak said, "As large pharmaceutical companies see their pipelines dwindling, they will need to turn to smaller companies...
Omeros (OMER) Files Orphan Drug Designation App for OMS721 w/ FDA
StreetInsider.com  Apr 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Omeros+%28OMER%29+Files+Orphan+Drug+Designation+App+for+OMS721+w+FDA/8258368.html for the full story.
Omeros Announces Positive Data for Model for Studying Multiple Sclerosis
Benzinga  Apr 10  Comment 
Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds...




more ▼WIKI ANALYSIS
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800.
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Omeros Corp (OMER):
 
Retrieved from "http://www.wikinvest.com/stock/Omeros_Corp_(OMER)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki